130 related articles for article (PubMed ID: 17900141)
1. Improved chemical syntheses of 5,6-dihydro-5-fluorouracil.
LaFrate AL; Katzenellenbogen JA
J Org Chem; 2007 Oct; 72(22):8573-6. PubMed ID: 17900141
[TBL] [Abstract][Full Text] [Related]
2. Excretion of 1-hexylcarbamoyl-5-fluorouracil in urine of mice.
Iigo M; Nakamura A; Kuretani K; Hoshi A
J Pharmacobiodyn; 1981 Jul; 4(7):490-6. PubMed ID: 6795334
[TBL] [Abstract][Full Text] [Related]
3. A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma.
Maring JG; Schouten L; Greijdanus B; de Vries EG; Uges DR
Ther Drug Monit; 2005 Feb; 27(1):25-30. PubMed ID: 15665742
[TBL] [Abstract][Full Text] [Related]
4. Systemic exposure to 5-fluorouracil and its metabolite, 5,6-dihydrofluorouracil, and development of a limited sampling strategy for therapeutic drug management of 5-fluorouracil in patients with gastrointestinal malignancy.
Jacob J; Mathew SK; Chacko RT; Aruldhas BW; Singh A; Prabha R; Mathew BS
Br J Clin Pharmacol; 2021 Mar; 87(3):937-945. PubMed ID: 32592630
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of cyclopentanyl carbocyclic 5-fluorocytosine ((-)-5-fluorocarbodine) using a facially selective hydrogenation approach.
Cho JH; Amblard F; Coats SJ; Schinazi RF
J Org Chem; 2013 Jan; 78(2):723-7. PubMed ID: 23231055
[TBL] [Abstract][Full Text] [Related]
6. Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics.
Maring JG; Piersma H; van Dalen A; Groen HJ; Uges DR; De Vries EG
Cancer Chemother Pharmacol; 2003 Feb; 51(2):167-73. PubMed ID: 12647019
[TBL] [Abstract][Full Text] [Related]
7. [Synthesis of 5-fluorouracil derivatives containing alkanoic acid].
Xu LH; Weng LL; Zheng H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jul; 37(4):644-6. PubMed ID: 16909623
[TBL] [Abstract][Full Text] [Related]
8. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
Schlemmer HP; Becker M; Bachert P; Dietz A; Rudat V; Vanselow B; Wollensack P; Zuna I; Knopp MV; Weidauer H; Wannenmacher M; van Kaick G
Cancer Res; 1999 May; 59(10):2363-9. PubMed ID: 10344745
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of N-acyl-2-(5-fluorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fluorouracil.
Lee JS; Jung YJ; Kim YM
J Pharm Sci; 2001 Nov; 90(11):1787-94. PubMed ID: 11745736
[TBL] [Abstract][Full Text] [Related]
10. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients.
McDermott BJ; van den Berg HW; Murphy RF
Cancer Chemother Pharmacol; 1982; 9(3):173-8. PubMed ID: 7160054
[TBL] [Abstract][Full Text] [Related]
11. [Synthesis and properties of 5-fluorouracil derivatives].
Semakov AV; Blinkov AA; Gaenko GP; Vostrova AG; Molotkovskiĭ IuG
Bioorg Khim; 2013; 39(3):338-45. PubMed ID: 24397032
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and properties of N-nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine ester as a prodrug of 5-fluorouracil for rectal administration.
Yang YW; Lee JS; Kim I; Jung YJ; Kim YM
Eur J Pharm Biopharm; 2007 May; 66(2):260-7. PubMed ID: 17182232
[TBL] [Abstract][Full Text] [Related]
13. A new method for the synthesis of N3-alkylated analogs of 5-fluorouracil.
Kozai S; Fukagawa T; Maruyama T
Nucleic Acids Symp Ser; 1999; (42):3-4. PubMed ID: 10780350
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship in Ftorafur (Tegafur) and related 5-FU prodrugs.
Zhuk R
Adv Exp Med Biol; 1998; 431():677-80. PubMed ID: 9598151
[No Abstract] [Full Text] [Related]
15. Synthesis of novel dioxane nucleosides having two bases, physico-chemical properties, and their biological activities.
Kajimoto N; Yamaizumi J; Aida M; Harada K; Maeda M
Nucleic Acids Symp Ser; 1997; (37):5-6. PubMed ID: 9585971
[TBL] [Abstract][Full Text] [Related]
16. Structure of 3-acetyl-5-fluorouracil (5-FU): implication for its rearrangements during hydrolysis and upon heating.
Beall HD; Prankerd RJ; Todaro LJ; Sloan KB
Pharm Res; 1993 Jun; 10(6):905-12. PubMed ID: 8321861
[TBL] [Abstract][Full Text] [Related]
17. Improved delivery through biological membranes. LXI: Design, synthesis, and evaluation of a lipolol-based intradermal drug targeting system for 5-fluorouracil.
Chikhale PJ; Marvanyos E; Bodor NS
Cancer Biother; 1994; 9(3):245-52. PubMed ID: 7820186
[TBL] [Abstract][Full Text] [Related]
18. Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
Yasumoto M; Moriyama A; Unemi N; Hashimoto S; Suzue T
J Med Chem; 1977 Dec; 20(12):1592-4. PubMed ID: 338900
[TBL] [Abstract][Full Text] [Related]
19. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of new 4beta-5-Fu-substituted 4'-demethylepipodophyllotoxin derivatives.
Zhang FM; Yao XJ; Tian X; Tu YQ
Molecules; 2006 Nov; 11(11):849-57. PubMed ID: 18007391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
